Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,766 active trials42 approved drugs708 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,441 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,353)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06175598 | Analysis of the Causes of Redo Pull-through for Recurrent Constipation and the Risk Factors Affecting the Prognosis of the Hirschsprung's Disease and Allied Disorders | completed | — | 79 | Feng JiexiongOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT05642988 | Application of Wearable Technology in High-risk Surgical Patients in the Perioperative Period | completed | — | 20 | Mater Misericordiae University HospitalOTHER | 1 | Dec 22, 2023 |
| clinicaltrials |
| NCT02626338 | Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML | completed | Phase 1 / Phase 2 | 16 | Arog Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 20, 2023 | clinicaltrials |
| NCT05028374 | COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies | completed | Phase 2 | 119 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT02400255 | Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients | completed | Phase 2 | 30 | Arog Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 18, 2023 | clinicaltrials |
| NCT03734601 | Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation | completed | Phase 2 | 22 | Stanford UniversityOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT01288378 | Empirical Versus Preemptive Antifungal Therapy | completed | Phase 3 | 556 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Dec 11, 2023 | clinicaltrials |
| NCT03919526 | Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor(CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL | completed | Phase 1 | 19 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Dec 8, 2023 | clinicaltrials |
| NCT02509546 | 8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 20 | City of Hope Medical CenterOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT00697684 | Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant | completed | Phase 1 | 29 | Beth Israel Deaconess Medical CenterOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT01145209 | Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL | completed | Phase 2 | 32 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Nov 28, 2023 | clinicaltrials |
| NCT06148493 | Real-World Usage of Asciminib Among Patients With Chronic Myeloid Leukemia in Chronic Phase in the United States Using a Large Claims Database | completed | — | 425 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 28, 2023 | clinicaltrials |
| NCT04786275 | Evaluation of the Nociception Guided by NoL Index and PK of Fentanyl in Pediatric Patients Under General Anesthesia(NoLPedFenta) | completed | — | 25 | Pontificia Universidad Catolica de ChileOTHER | 1 | Nov 27, 2023 | clinicaltrials |
| NCT03455517 | Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia(VeRitAs) | completed | Phase 2 | 77 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT01523223 | Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies | completed | Phase 1 | 16 | Robert LowskyOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT03677596 | A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients | completed | Phase 4 | 102 | PfizerINDUSTRY | 8 | Nov 22, 2023 | clinicaltrials |
| NCT04853277 | Patient Reported Outcomes and Patient Education in Cellular Therapy Patients | completed | N/A | 31 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05059756 | PTNS and PFR in the Treatment of Childhood Constipation | completed | N/A | 84 | Shengjing HospitalOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT02543879 | Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies | completed | Phase 1 | 94 | Forma Therapeutics, Inc.INDUSTRY | 1 | Nov 21, 2023 | clinicaltrials |
| NCT02733042 | A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia(FUSION NHL 001) | completed | Phase 1 / Phase 2 | 106 | CelgeneINDUSTRY | 7 | Nov 18, 2023 | clinicaltrials |
| NCT03961919 | Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant(FLAT-Auto) | completed | Phase 2 | 15 | Ciceri FabioOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT04145531 | An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) | completed | Phase 2 / Phase 3 | 229 | Jazz PharmaceuticalsINDUSTRY | 2 | Nov 18, 2023 | clinicaltrials |
| NCT03298984 | Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML). | completed | Phase 1 | 32 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 15, 2023 | clinicaltrials |
| NCT00047060 | Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome | completed | Phase 1 / Phase 2 | 5 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Nov 14, 2023 | clinicaltrials |
| NCT00321555 | LMB-2 to Treat Hairy Cell Leukemia | completed | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Nov 14, 2023 | clinicaltrials |
| NCT02498665 | A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies | completed | Phase 1 | 24 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 14, 2023 | clinicaltrials |
| NCT01823198 | Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies | completed | Phase 1 / Phase 2 | 63 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT02639559 | Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies | completed | Phase 2 | 50 | Washington University School of MedicineOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT03613727 | Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients | completed | Phase 2 | 61 | Virginia Commonwealth UniversityOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT03671564 | Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) | completed | Phase 1 | 14 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | Nov 7, 2023 | clinicaltrials |
| NCT04055844 | Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS | completed | Phase 2 | 14 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT02782468 | A Study of Pevonedistat in Adult East Asian Participants | completed | Phase 1 | 23 | Millennium Pharmaceuticals, Inc.INDUSTRY | 3 | Nov 3, 2023 | clinicaltrials |
| NCT02989844 | Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT | completed | Phase 2 | 20 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 3, 2023 | clinicaltrials |
| NCT03728699 | Microbiota Changes in Acute Myeloid Leukemia Patients Undergoing Intensive Chemotherapy | completed | — | 54 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 3, 2023 | clinicaltrials |
| NCT02547662 | Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia | completed | Phase 2 | 17 | Mayo ClinicOTHER | 1 | Oct 30, 2023 | clinicaltrials |
| NCT01404741 | 5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS) | completed | Phase 2 | 191 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT03262974 | Effect of Pharmacogenetics on Imatinib Plasma Level and Response | completed | — | 60 | Assiut UniversityOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT02117297 | SCT Plus Immune Therapy in Average Risk AML/MDS | completed | Phase 2 | 26 | New York Medical CollegeOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT02221310 | Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS | completed | Phase 2 | 25 | New York Medical CollegeOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT00571662 | Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant | completed | Phase 2 | 76 | University of NebraskaOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT00611351 | Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer | completed | Phase 2 | 5 | University of NebraskaOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT02869633 | Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant | completed | Phase 2 | 23 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT06095726 | Peppermint Inhalation Versus Swedish Massage on Chemotherapy Induced-Nausea and Vomiting in Children With Leukemia | completed | N/A | 75 | Alexandria UniversityOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT03916237 | Registry and Screening Tool to Identify Children With Asthma Likely to Benefit From Home Assessment and Remediation(CREST) | completed | N/A | 21 | MetroHealth Medical CenterOTHER | 1 | Oct 19, 2023 | clinicaltrials |
| NCT04198415 | A Study of the Safety and Efficacy of Venetoclax in Japanese Participants With Relapsed and Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Leukemia)(VENCLL regPMOS) | completed | — | 4 | AbbVieINDUSTRY | 1 | Oct 19, 2023 | clinicaltrials |
| NCT02916979 | Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG(FluBuATG) | completed | Phase 1 | 20 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT03701295 | Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement | completed | Phase 1 / Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Oct 18, 2023 | clinicaltrials |
| NCT02005471 | A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)(MURANO) | completed | Phase 3 | 389 | Hoffmann-La RocheINDUSTRY | 20 | Oct 17, 2023 | clinicaltrials |
Data updated 24 days agoSource updated Dec 27, 2023source: clinicaltrials